Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Acquire BioReliance for $350M

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to acquire BioReliance Holdings from Avista Capital Partners for $350 million in cash.

Rockville, Md.-based BioReliance provides biologic, specialized toxicology, and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers. The firm had full-year 2010 revenues of around $110 million and is expected to post double-digit growth for 2011.

Avista had acquired BioReliance nearly five years ago from Invitrogen, now part of Life Technologies, for $210 million.

"The addition of BioReliance's industry-leading QA/QC testing services enables us to support customers' needs to determine the quality and integrity of biological drugs at every step of the development and manufacturing process," Sigma-Aldrich President and CEO Rakesh Sachdev said in a statement.

The deal is expected to close this quarter, and Sigma-Aldrich said that it expects the transaction to be "mostly accretive" to its earning per share in 2012.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.